Acral Melanoma Outcomes Differ Across Racial Groups
Health Professionals
Neoadjuvant Vidutolimod Plus Pembrolizumab Elicits Responses and Is Safe in Stage III Melanoma
Neoadjuvant Vidutolimod Plus Pembrolizumab Elicits Responses and Is Safe in Stage III Melanoma
Comparing Adjuvant Immunotherapy vs Targeted Therapy in Stage III BRAF-Mutant Melanoma
Comparing Adjuvant Immunotherapy vs Targeted Therapy in Stage III BRAF-Mutant Melanoma
Frontline Immunotherapy Treatment Options in Advanced or Metastatic Cutaneous Melanoma
Frontline Immunotherapy Treatment Options in Advanced or Metastatic Cutaneous Melanoma